TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX) will present at the TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 11:50 a.m. ET in Boston.

The hybrid presentation includes an analyst Q&A and a live webcast via the company’s Events and Presentations page, with an archived replay available for 90 days.

News Market Reaction – TCRX

+5.71%

4 alerts

+5.71% Session close to close

+8.1% Peak Tracked

-5.4% Trough Tracked

$64.13M Market Cap

0.1x Rel. Volume

In the Feb 25 session, TCRX gained 5.71%, reflecting a notable positive market reaction. Argus tracked a peak move of +8.1% during that session. Argus tracked a trough of -5.4% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.7% in the session following this news. A strong positive reaction aligns with TSc...

Analysis

The stock moved +5.7% in the session following this news. A strong positive reaction aligns with TScan’s pattern of using conferences and KOL events to spotlight its TCR-T pipeline and pivotal plans for TSC-101. With shares trading well below the $2.57 52-week high and under the $1.49 200-day MA, investors previously reacted inconsistently to clinical and strategic updates. Conference-driven strength could be sensitive to subsequent data releases or corporate decisions that historically produced both rallies and sharp declines.

Key Figures

Conference edition: 46th Annual Conference date: March 4, 2026 Presentation time: 11:50 a.m. ET +1 more

4 metrics

Conference edition 46th Annual TD Cowen Health Care Conference

Conference date March 4, 2026 Presentation schedule at TD Cowen conference

Presentation time 11:50 a.m. ET Scheduled presentation time at conference

Webcast replay period 90 days Archived replay available after the event

Historical Context

5 past events · Latest: Dec 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 06	Clinical data update	Positive	-7.4%	Updated ALLOHA Phase 1 data with improved survival and no DLTs.
Dec 03	KOL event announced	Positive	+7.1%	Announcement of virtual KOL event on ALLOHA data and heme market.
Nov 12	Earnings and update	Positive	-2.5%	Q3 2025 results with higher revenue and extended cash runway.
Nov 05	Conference participation	Neutral	+1.3%	Participation in Guggenheim healthcare innovation conference webcast.
Nov 03	Strategic reprioritization	Negative	-36.1%	Pivotal design for TSC-101 plus workforce reduction and cost savings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news shows mixed alignment: positive clinical and strategic updates sometimes saw negative reactions, with 3 aligned moves and 2 divergences over the last 5 events.

Recent Company History

Over the past few months, TScan highlighted pivotal trial alignment with the FDA for TSC-101, a workforce reduction of 30% or 66 employees, and extended cash runway into H2 2027. Clinical updates from the ALLOHA™ Phase 1 trial, including improved survival trends and a manufacturing time cut from 17 to 12 days, framed the heme program as the core focus. The company also actively participated in healthcare conferences, making this TD Cowen participation consistent with prior investor outreach efforts.

Key Terms

t cell receptor, tcr-t, webcast

3 terms

t cell receptor medical

"focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies"

A T cell receptor is a protein sensor on the surface of certain immune cells that recognizes small pieces of foreign or abnormal material, like fragments of a virus or a cancer cell, and helps trigger an immune response. Investors care because therapies and diagnostics that target or use these receptors act like reprogramming a security scanner to find specific threats, so success or failure in developing safe, effective T cell receptor–based drugs or tests can strongly affect a biotech company's value.

tcr-t medical

"T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients"

TCR‑T is a type of engineered cell therapy where a patient’s T cells are reprogrammed to carry specific T‑cell receptors that recognize fragments of disease proteins presented on the surface of cells. Think of it as giving immune cells a custom key to find and attack cells displaying a particular molecular “badge.” For investors, TCR‑T represents a high‑precision, potentially powerful treatment approach with significant commercial upside but also complex manufacturing, regulatory hurdles and safety risks that can affect development timelines and valuation.

webcast technical

"A webcast of the presentation will be available on the “Events and Presentations” section"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a hybrid presentation followed by an analyst-led Q&A session at the TD Cowen 46^th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, MA on Wednesday, March 4, 2026 at 11:50 a.m. Eastern Time.

A webcast of the presentation will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidate is in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA^™ Phase 1 heme trial). The Company has developed multiple TCR-T therapy candidates for solid tumors and is currently developing methods for in vivo engineering using these candidates. The Company is also applying their target discovery platform to discover novel targets in various T cell-mediated autoimmune disorders.

Contacts

Troy Neubecker
TScan Therapeutics, Inc.
Investor Relations
857-399-9517
tneubecker@tscan.com

Caileigh Dougherty
Media Contact
857-399-9890
cdougherty@tscan.com

FAQ

When will TScan Therapeutics (TCRX) present at the TD Cowen Health Care Conference?

TScan will present on March 4, 2026 at 11:50 a.m. ET, with an analyst-led Q&A immediately after. According to the company, the session is hybrid and will be held at the Boston Marriott Copley Place in Boston, MA.

How can investors watch the TScan Therapeutics (TCRX) presentation on March 4, 2026?

Investors can watch a live webcast through the company’s Events and Presentations page at ir.tscan.com. According to the company, a webcast will be available live and an archived replay will be posted for later viewing.

Will TScan Therapeutics (TCRX) provide a replay of its TD Cowen presentation and for how long?

Yes. An archived replay will be available on the company website for 90 days after the event. According to the company, investors can access the replay from the Events and Presentations section at ir.tscan.com.

What format will TScan Therapeutics' (TCRX) TD Cowen session use and who will lead the Q&A?

The session will be a hybrid presentation followed by an analyst-led Q&A. According to the company, the format combines an in-person presentation at the conference with a webcast for remote investors.

Where is the TD Cowen 46th Annual Health Care Conference taking place for TScan Therapeutics (TCRX)?

The conference is at the Boston Marriott Copley Place in Boston, MA. According to the company, TScan’s hybrid presentation will be delivered from that venue on March 4, 2026 at 11:50 a.m. Eastern Time.